NBIX vs SNGX · P/E 45, rev $1.77B vs $6.0M cap
Neurocrine Biosciences Inc (NBIX) versus Soligenix Inc. (SNGX) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Soligenix Inc. (SNGX) is a biotechnology company listed on NASDAQ.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
SNGX does not have a complete income-statement cache yet.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. SNGX currently screens at market cap $6.0M.
Not investment advice. Open the NBIX and SNGX stock pages for the full models.
Not investment advice.